Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03136484 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 788
- Enrollment target
NCT03136484: Completed Phase 3 study, sponsored by Novo Nordisk A/S.
NCT03136484 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 788 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03136484, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 788 participants
- Enrollment target
Study Summary
This trial is conducted in Africa, Asia, Europe, North and South America. The aim of the trial is to compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0 mg) versus once-daily dosing of oral canagliflozin (300 mg) on glycaemic control in subjects with type 2 diabetes (T2D) on a background treatment of metformin
Primary Outcome
Change from baseline (week 0) to week 52 in HbA1c (glycosylated haemoglobin) was evaluated. Results are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose to either the day of last dose plus 7 days or first initiation of rescue medication, whichever came first; and 'In-trial' observation period which started at the date of randomisation and include the period after initiation of rescue medication and/or premature trial product discon
Interventions
- DRUG Semaglutide
- DRUG Placebo (semaglutide)
- DRUG Canagliflozin
- DRUG Placebo (canagliflozin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 788 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2018-11-16 |
| Phase | Phase 3 |
What the finished NCT03136484 record still lists
NCT03136484 is an interventional study that assigns participants to a tested intervention. The registered 788 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Semaglutide is the first listed.
NCT03136484 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03136484 about?
NCT03136484 is a clinical study titled "Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes". This trial is conducted in Africa, Asia, Europe, North and South America. The aim of the trial is to compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0 mg) versus once-daily dosing of oral canagliflozin (300 mg) on glycaemic control in subjects with type 2 diabetes (T2D) ...
What is the current status of trial NCT03136484?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 788 participants. The study started on 2017-03-15. Estimated completion is 2018-11-16.
What interventions are being tested in trial NCT03136484?
The interventions under investigation include: Semaglutide (DRUG), Placebo (semaglutide) (DRUG), Canagliflozin (DRUG), Placebo (canagliflozin) (DRUG).
Who is sponsoring clinical trial NCT03136484?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03136484's enrollment target sits among peer trials
788 431st of 2000 higher than 1,570 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06488781 · 787 participants · Phase 2
Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0
- NCT06876649 · 787 participants · Phase 4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- NCT04967989 · 790 participants · Phase 3
Clarifying the Optimal Application of SLT Therapy Trial
- NCT06162611 · 790 participants · Phase 4
Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI